Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Endo Health Solutions Inc Reaffirms FY 2012 Guidance-Conference Call
Endo Health Solutions Inc announced that for fiscal 2012, it expects total revenues of $3.05 billion, adjusted diluted earnings per share (EPS) in the range of $5.00 to $5.10 and GAAP diluted earnings per share in the range of $0.87-$0.97. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $3.05 billion and EPS of $5.01 for fiscal 2012.
Latest Developments for Endo Health Solutions Inc
Latest Key Developments in Pharmaceuticals
- Tonghua Golden-Horse Pharmaceutical Industry Co Ltd Announces Changes of General Manager
- Merck & Co Inc Announces $5 Billion Accelerated Share Repurchase
- Herbalife Ltd Engages PricewaterhouseCoopers LLP As Auditors
- Drug regulator to probe Ranbaxy Laboratories Ltd's records, approvals in India-Business Standard
- Share this
- Link this
- Digg this
Follow Reuters